Our Fight
Twenty lives are lost every minute to cancer. By 2040, worldwidethere will be 30.2 million new cancer cases and 16.3 million cancer deaths. Each cancer is caused by a unique combination of over 6 million potential mutations of 600+ cancer genes. The targeted therapies that currently exist are focused on only some of the most frequent cancer genes... and often fail to work due to the complex, unique molecular background of each tumor.
Our Solution
Our dream is that one day all cancer patients will be cured if we can target the molecular cause of their cancer. Cancer is very complex, being caused by combinations of genetic mutations out of thousands of possible mutations. But we believe that, by using the power of computer science, we can outsmart cancer and beat it at its own game. To achieve this, we have built Genomate, a powerful computational (open box AI) tool to improve treatment decisions in precision oncology and to find the right targeted therapy for every cancer patient based on the individual molecular profile of their tumor. We want to improve, automate, democratize precision oncology to make it better, faster, and more affordable for all cancer patients by improving and automatizing decision-making in oncology.
How Does it Work?
1. The patient’s tumor is analyzed by CLIA-certified molecular diagnostic laboratories.
2. Genetic alterations found in the tumor are uploaded into the Genomate system.
3. Genomate assigns predictive scores to targeted therapies to help the physician's treatment decisions. The output is an AI-assisted personalized digital therapy plan created by the oncologist based on all available molecular diagnostic information.
What Do Physicians Say?
“Starting to integrate AI for treatment decisions in oncology.”
“SHIVA01 was the first randomized precision oncology clinical trial. Now, with the help of DDA (Genomate technology), we can base our decisions on multiple parameters and rare alterations, making the next step toward the full implementation of the concept of precision oncology”.
Prof. Christophe Le Tourneau
Institut Curie, Paris, 2021
Why does this
solution work?
Genomate’s technology is a clinical decision support system, that has been scientifically validated based on clinical trial data.* The system is an open box, explainable, rule-based computational AI tool. This means that Genomate uses human intelligence augmented with computational power. The system automatically calculates an aggregated evidence level (AEL) of genetic alterations and their associated druggable targets and molecularly targeted therapies. Instead of reporting cancer gene–treatment associations and related pieces of evidence one by one, the system automatically combines all information from thousands evidence associated to the totality of genetic alterations in the same tumor to create a simple score in 20 milliseconds.
*Peták, I., Kamal, M., Dirner, A. et al. A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial. npj Precis. Onc. 5, 59 (2021) (reporting on findings generated in collaboration with oncologists at the Institute Curie (Paris). https://www.nature.com/articles/s41698-021-00191-2
About Genomate Health
Genomate Health Inc. is a digital health company (Cambridge, MA, USA) that develops computational (AI) tools for personalized medicine (“genomates”) that physicians can use to always make the best, personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases. Genomate Health is a spin-out and partner company of Oncompass Medicine (Budapest, Hungary) that developed the Digital Drug Assignment (DDA) technology.
We want to be your partner on precision oncology. Contact us for more information: info@genomate.health.
Scientific Publications
1. A computational method for prioritizing targetedtherapies in precision oncology: performance analysis in the SHIVA01 trial.
Petak I, Kamal M, Dirner A, Bieche I, Doczi R, Mariani O, Filotas P, Salomon A, Vodicska B, Servois V, Varkondi E, Gentien D, Tihanyi D, Tresca P, Lakatos D, Servant N, Deri J, du Rusquec P, Hegedus C, Bello Roufai D, Schwab R, Dupain C, Valyi-Nagy IT, Le Tourneau C.
NPJ Precis Oncol. 2021 Jun 23;5(1):59. doi: 10.1038/s41698-021-00191-2. PMID: 34162980; PMCID: PMC8222375.
2. Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.
Remenár É, Dóczi R, Dirner A, Sipos A, Perjési A, Tihanyi D, Vodicska B, Lakatos D, Horváth K, Kajáry K, Schwáb R, Déri J, Lengyel CG, Várkondi E, Vályi-Nagy I, Peták I.
JCO Precis Oncol. 2022 Jan;6:e2100344. doi: 10.1200/PO.21.00344. PMID: 35005996.
3. Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support.
Szkukalek J, Dóczi R, Dirner A, Boldizsár Á, Varga Á, Déri J, Lakatos D, Tihanyi D, Vodicska B, Schwáb R, Pajkos G, Várkondi E, Vályi-Nagy I, Valtinyi D, Nagy Z, Peták I.
Diagnostics (Basel). 2021 Oct 7;11(10):1850. doi: 10.3390/diagnostics11101850. PMID: 34679548; PMCID: PMC8534772.
4. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L, Dóczi R, Vodicska B, Tihanyi D, Horváth M, Kormos D, Takács I, Pápai-Székely Z, Póka-Farkas Z, Várkondi E, Schwáb R, Hegedüs C, Vályi-Nagy I, Peták I.
Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18. PMID: 33082101.
5. Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC.
Urbán L, Dóczi R, Vodicska B, Kormos D, Tóth L, Takács I, Várkondi E, Tihanyi D, Lakatos D, Dirner A, Vályi-Nagy I, Peták I.
J Pers Med. 2020 Aug 28;10(3):107. doi: 10.3390/jpm10030107. PMID: 32872120; PMCID: PMC7563786.
Our accomplishments
Future Unicorn Award: Most promising
technology company in Europe
2021 edition
Breakthrough Innovations (AI) in Oncology Conference Award 2019
CLINICAL ONCOLOGY
Global Champion
109 countries, 25,000 applicants
COMPETITION IN 2021
”
“
Could be the next
scientific revolution.
“Could be the next scientific revolution.”
Ursula von der Leyen
